Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects

• Published in: Advances in therapy Vol. 37; no. 10; pp. 4291 - 4307
• Main Authors: Finck, Barbara, Tang, Helen, Civoli, Francesca, Hodge, Jennifer, O’Kelly, Hillary, Vexler, Vladimir
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.10.2020
• Subjects: Cardiology; Cross-Over Studies; Endocrinology; Filgrastim; Granulocyte Colony-Stimulating Factor; Healthy Volunteers; Humans; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Polyethylene Glycols; Recombinant Proteins; Rheumatology; Single-Blind Method; Supportive care; Chemotherapy-induced febrile neutropenia; Pegfilgrastim; Granulocyte colony-stimulating factors; Pegfilgrastim-cbqv; Biosimilar
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-020-01459-y

Introduction Pegfilgrastim-cbqv was developed as a biosimilar of pegfilgrastim, a pegylated form of recombinant human granulocyte colony-stimulating factor approved for decreasing febrile neutropenia-associated infection in patients receiving myelosuppressive drugs. This multicenter, randomized, single-blind, partial-reference-replicated, three-sequence crossover study assessed pharmacokinetic and pharmacodynamic bioequivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects. Methods One hundred twenty-two subjects were randomized to one of three treatment sequences; each included one dose of pegfilgrastim-cbqv and two doses of pegfilgrastim separated by ≥ 28 days. The primary pharmacokinetic end points were area under the curve (AUC) from 0 to infinity (AUC 0−∞ ) and maximum concentration ( C max ). The primary pharmacodynamic end points were maximum absolute neutrophil count (ANC max ) and ANC AUC from time 0 to the last measurable observation (ANC AUC 0−last ). Pharmacokinetic and pharmacodynamic bioequivalences were demonstrated if the 90% CI for the geometric mean ratio (GMR) of pegfilgrastim-cbqv to pegfilgrastim was within 80–125% for the primary end points. Results Pharmacokinetic bioequivalence criteria were met for C max (GMR 105.0; 90% CI 95.5–115.4) and AUC 0−∞ (GMR 97.5; 90% CI 88.6–107.2). Pharmacodynamic bioequivalence criteria were met for ANC max (GMR 99.6; 90% CI 96.2–103.2) and ANC AUC 0−last (GMR 96.7; 90% CI 92.2–101.4). Adverse events occurred in 76.0%, 76.6%, and 73.1% of subjects for pegfilgrastim-cbqv, first pegfilgrastim, and second pegfilgrastim dosing periods across treatment sequences, respectively. Investigators found no drug-related serious adverse events. Conclusion This study established pharmacokinetic and pharmacodynamic bioequivalence of pegfilgrastim-cbqv to pegfilgrastim. The treatments displayed similar safety profiles, including immunogenicity, with no unexpected safety findings. Clinical Trials Registration ClinicalTrials.gov, NCT02650973, February 2016.